Take a look at our previous reports:

Annual Report

2015

View Report

Q1 Report

2016

View Report

H1 Report

2016

View Report

Q3 Report

2016

View Report
English | Dutch
Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2016

  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos group
    • Letter from the management
    • Committed to moving forward
      • Walid Abi-Saab
      • Ellen van der Aar
      • Veronique Deiteren
    • At a glance
    • Strategy
    • Going concern statement
    • Risk management and internal control
    • The Galapagos share
    • Subsequent events
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • The Galapagos pipeline
    • Target discovery platform
    • Rheumatoid arthritis
      • Filgotinib program in RA
    • Inflammatory bowel disease
      • Filgotinib program in IBD
      • Clinical program with filgotinib in CD
      • Clinical program with filgotinib in UC
    • Cystic fibrosis
      • Clinical program for CF
    • Idiopathic pulmonary fibrosis
    • Osteoarthritis
    • Atopic dermatitis
  • Risk factors
    • Financial position and need for additional capital
    • Product development, regulatory approval and commercialization
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • Corporate governance
    • Policies
    • Board of directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Determination of remuneration
      • Remuneration policy
      • Non-executive directors
      • Executive directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other executive committee members
      • Shares, warrants or other rights
      • Severance payments
      • Severance payments in 2016
      • Claw-back right
    • Conflict of interests and related parties
    • Statement by the board of directors
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Significant accounting policies
        • 3. Critical accounting estimates and judgments
        • 4. Segment information
        • 5. Total revenues and other income
        • 6. Operating costs
        • 7. Staff costs
        • 8. Fair value re-measurement of share subscription agreement
        • 9. Other financial income/expenses
        • 10. Taxes
      • Notes 11-20
        • 11. Result per share
        • 12. Intangible assets
        • 13. Property, plant and equipment
        • 14. Other non-current assets
        • 15. Research and Development incentives receivables
        • 16. Restricted cash
        • 17. Trade and other receivables and other current assets
        • 18. Cash and cash equivalents
        • 19. Share capital
        • 20. Other reserves
      • Notes 21-30
        • 21. Translation differences
        • 22. Deferred tax
        • 23. Finance lease liabilities
        • 24. Trade and other liabilities
        • 25. Provisions
        • 26. Operating lease obligations
        • 27. Off-balance sheet arrangements
        • 28. Contingent assets and liabilities
        • 29. Retirement benefit plans
        • 30. Warrant plans
      • Notes 31-35
        • 31. Related parties
        • 32. Consolidated companies as of 31 December 2016
        • 33. Financial risk management
        • 34. Statutory auditor’s remuneration
        • 35. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor

Financial statements

  • Consolidated financial statements
  • Notes to the consolidated financial statements
    • Notes 1-10
    • Notes 11-20
      • 11. Result per share
      • 12. Intangible assets
      • 13. Property, plant and equipment
      • 14. Other non-current assets
      • 15. Research and Development incentives receivables
      • 16. Restricted cash
      • 17. Trade and other receivables and other current assets
      • 18. Cash and cash equivalents
      • 19. Share capital
      • 20. Other reserves
    • Notes 21-30
    • Notes 31-35
  • Non-consolidated financial statements

You are here:

  • Home
  • Financial statementsNotes to the consolidated financial statements
  • Notes 11-20
  • Notes 11-20
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
Notes 11-20

Notes 11-20

  • 11. Result per share
  • 12. Intangible assets
  • 13. Property, plant and equipment
  • 14. Other non-current assets
  • 15. Research and development incentives receivables
  • 16. Restricted cash
  • 17. Trade and other receivables and other current assets
  • 18. Cash and cash equivalents
  • 19. Share capital
  • 20. Other reserves
previous pagenext page
Download Center
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 23 March 2017

Galapagos Annual Report 2016 (PDF)

Download the entire report as PDF.

Download PDF (3.3 MB)
English | Dutch
  • Downloads
  • Glossary of terms
  • © Copyright 2017 Galapagos NV
  • Colophon
  • Contact
  • Sitemap
© Copyright 2017 Galapagos NV
nexxar - digital reporting evolved - Online Report